Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 13:15 save search
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Published: 2021-11-09 (Crawled : 13:15) - inovio.com
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 4.79%
H: 7.71%
C: 0.71%
covid fda vaccine phase 3 ino-4800
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance
Published: 2021-11-09 (Crawled : 13:15) - biospace.com/
ALDX | $3.94 0.77% 0.51% 530K
|
Health Technology
|
| O: 1.11%
H: 3.41%
C: 1.76%
new drug dry eye disease eye application eye disease drug phase 3 trial submission enroll
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
Published: 2021-10-18 (Crawled : 13:15) - biospace.com/
RDUS | $17.91 1.53% 1.45% 320K
|
Health Technology
|
| O: -1.31%
H: 6.97%
C: 5.98%
positive injection results topline phase 3 osteoporosis abaloparatide tymlos
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 13.26%
H: 1.2%
C: -16.0%
positive results topline biotech phase 3 iot
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-10-06 (Crawled : 13:15) - biospace.com/
SAVA M | $20.74 0.93% 0.96% 450K
|
Health Technology
|
| O: -0.51%
H: 5.45%
C: -7.68%
disease alzheimer treatment phase 3 trial refocus-alz rethink-alz alzheimer’s alzheimer's disease alzheimer's
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
Published: 2021-09-29 (Crawled : 13:15) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.12%
H: 1.02%
C: 0.63%
respiratory vaccine phase 3 trial order
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Published: 2021-09-29 (Crawled : 13:15) - globenewswire.com
EDIT | News | $5.35 -2.02% -1.96% 1.2M
|
Health Technology
|
| O: -6.58%
H: 2.45%
C: -13.27%
ongoing phase 1 positive trial phase 2 phase 3
Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients
Published: 2021-09-20 (Crawled : 13:15) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -2.36%
H: 1.28%
C: -0.14%
covid biopharma phase 3
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab
Published: 2021-09-15 (Crawled : 13:15) - biospace.com/
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.1%
H: 2.07%
C: 1.11%
CHRS | $2.02 -7.34% -7.39% 630K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.29%
results phase 3
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
Published: 2021-08-17 (Crawled : 13:15) - biospace.com/
MEIP | $3.26 -2.17% -2.22% 7.4K
|
Health Technology
|
| O: -1.86%
H: 1.89%
C: 0.38%
phase 3 t-cell
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
Published: 2021-07-19 (Crawled : 13:15) - biospace.com/
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.62%
H: 0.78%
C: 0.07%
ARDS | $0.063 -0.79% 2.82% 30K
|
Health Technology
|
| O: -0.69%
H: 2.94%
C: -12.59%
antibody license phase 3
Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 13:15) - crinetics.com
CRNX G | $43.32 -2.04% -2.08% 490K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
Published: 2021-06-10 (Crawled : 13:15) - nantkwest.com
IBRX | $4.82 -12.2% -14.02% 7.4M
|
Manufacturing
|
| O: 0.2%
H: 2.21%
C: -3.24%
phase 2 phase 1 therapy hiv phase 3 injection infections
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
Published: 2021-06-09 (Crawled : 13:15) - biospace.com/
OMER | $3.04 -1.62% -1.64% 250K
|
Health Technology
|
| O: 0.95%
H: 2.0%
C: 0.25%
phase 1 results trial phase 3 phase 2
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
TCON | $1.89 2.16% 2.37% 66K
|
Health Technology
|
| O: 2.95%
H: 1.11%
C: -6.05%
IMAB | $1.81 0.56% 0.28% 110K
|
Health Technology
|
| O: 0.01%
H: 5.28%
C: 2.46%
phase 1 phase 3 phase 2
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
CLDX | $37.02 -1.99% -2.15% 390K
|
Health Technology
|
| O: 0.86%
H: 1.36%
C: -1.41%
ongoing phase 1 trial phase 3 phase 2
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
GTHX | $3.99 -4.77% -5.28% 340K
|
Health Technology
|
| O: 0.47%
H: 0.42%
C: -1.04%
phase 1 cancer breast cancer phase 3 her2+ her2- her2
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Published: 2021-06-03 (Crawled : 13:15) - globenewswire.com
TNXP | $0.16 2.04% 1.2% 940K
|
Health Technology
|
| O: 0.0%
H: 3.23%
C: 0.0%
positive results positive results phase 3 fibromyalgia
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA NephropathyTopline data from interim 36-week proteinuria endpoint expected in August 2021
Published: 2021-06-02 (Crawled : 13:15) - biospace.com/
TVTX | $5.45 -5.05% -5.13% 940K
|
Health Technology
|
| O: -0.76%
H: 0.21%
C: -0.07%
topline nephropathy phase 3 enroll
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
Published: 2021-05-26 (Crawled : 13:15) - biospace.com/
APVO | $0.6826 -7.28% -7.84% 560K
|
Health Technology
|
| O: 8.87%
H: 9.09%
C: -8.0%
myeloid leukemia phase 1 positive drug leukemia phase 3 phase 2 apvo436 acute myeloid leukemia
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.